The functions about Enoxaparin Sodium

Enoxaparin Sodium is a low molecular weight heparin marketed under the trade names Lovenox, Xaparin and Clexane, among others. It is an anticoagulant used to prevent and treat deep vein thrombosis or pulmonary embolism, and is given as a subcutaneous injection (by a health care provider or the patient). Its use is evolving in acute coronary syndromes (ACS).
Enoxaparin Sodium is manufactured by Sanofi and is derived from the intestinal mucosa of pigs.
Enoxaparin Sodium injection, USP is a low molecular weight heparin [LMWH] indicated for:
Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness.
Inpatient treatment of acute DVT with or without pulmonary embolism
Outpatient treatment of acute DVT without pulmonary embolism. 
Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction MI
Treatment of acute ST-segment elevation myocardial infarction STEMI managed medically or with subsequent percutaneous coronary intervention PCI

Reamore:Enoxaparin Sodium online
The article reprinted from:http://www.acid-lactic-bacteria.com/blog/post11/

Changes in the pharmacokinetics of the low-molecular-weight heparin Enoxaparin sodium during pregnancy

Objective

We wanted to assess the pharmacokinetics of subcutaneously administered Enoxaparin sodium during and after pregnancy. Study Design: Daily subcutaneous injections of Enoxaparin sodium (40 mg) were administered to 13 pregnant women. On three separate occasions, once early in pregnancy (12-15 weeks), even late in pregnancy (30-33 weeks), and once in the nonpregnant state (6-8 weeks post pactum), serial blood samples collected, and plasma was analyzed for anti-factor Ea activity. Analysis of variance was used for statistical analysis. P <0.05 was significant. Results: The time to maximum concentration and the mean residence time in the pregnancy compared with the state after the birth did not differ significantly. During the early and late pregnancy, maximum concentration and the last measurable anti-factor Ea activity were lower than in non-pregnant state (P <.05). The area under the plasma activity-versus-time curve was significantly lower than during pregnancy in the postpartum state (P <.05). Conclusion: The pharmacokinetics of Enoxaparin sodium are significantly different during pregnancy than in the same, if not pregnant women. The observed difference is probably due to the increased renal clearance of Enoxaparin during pregnancy. This finding has significant implications for appropriate dosing of Enoxaparin in pregnancy.

Read More:Enoxaparin-Sodium sales